01548.HK
Genscript Biotech Corporation
HKSE · Healthcare · Biotechnology · CN
HKD 31.46
−13.33%Year over year
Reported trailing growth
- Revenue
- +16.1%
- EBITDA
- +178.8%
- EBIT
- +145.7%
- EPS
- —
- Free cash flow
- +130.4%
- Operating cash flow
- +222.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +15.3%
- EBITDA
- +95.0%
- EBIT
- +212.2%
- Net income
- —
- EPS
- —
- Free cash flow
- +434.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026